Identification of Early Markers for ALS

Recruiting N/A Interventional Study
Amyotrophic Lateral Sclerosis (ALS)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
60 (estimated)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available. Due to the already advanced, disease stage at the time of diagnosis as well as rapid disease progression, an early diagnosis is mandatory for efficacious disease-modifying therapies. In this project, the investigators will devel…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: FIRST GROUP: Premotor gene mutation carriers (PGMC): * 18-90 years of age * Provision of a written informed consent * Affiliation with a social security scheme or beneficiary of such a scheme * Diagnosed by a clinically certified laboratory with a disease- causing mutation in a…
Contacts

Philippe CORCIA, Professor

+33247473724

philippe.corcia@univ-tours.fr

CONTACT